| Property | Value |
|---|
|
?:abstract
|
-
Acute respiratory distress syndrome (ARDS) is a most common complication in patients with severe COVID-19 with high rate of mortality Corticosteroids have been used in the management of SARS-CoV and MERS-CoV several years ago Data about the effectiveness of corticosteroids in the management of COVID-19 is lacking It has been proposed that the corticosteroids have a modulatory effect by suppressing cytokine storms in severe COVID-19 The aimed of this study is to review literature that discussed the use of corticosteroids in patients with COVID-19 related ARDS Pubmed database was used to select the article in this review with the keywords SARS-CoV-2, COVID-19, corticosteroid, pneumonia, and ARDS Elderly and patients with underlying disease are more likely to develop severe COVID-19 and lead to ARDS Because of the immunosuppressive activity, corticosteroid could modulate the cytokine storms in COVID-19 patients with ARDS The use of corticosteroids may offer the benefit in COVID-19 with ARDS, by reduce the mortality rate and duration of treatment The administration of corticosteroids should be considered in COVID-19 patients with signs of ARDS and refractory shock The low until moderate dose and short treatment of corticosteroids are recommended to minimize the adverse effects
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Pharmaceutical_Sciences_Asia
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
The role of corticosteroid for the treatment of Coronavirus disease-2019 (COVID-19): A narrative review
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}